Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
Nature Communications
|
June 14, 2018
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
Mariangela Russo, Simona Lamba, Annalisa Lorenzato, et al.
Science Translational Medicine
|
February 21, 2014
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
Sandra Misale, Sabrina Arena, Simona Lamba, et al.
The Journal of Clinical Investigation
|
July 29, 2010
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
June 19, 2024
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification
Marco Cortese, Erica Torchiaro, Alice D'Andrea, et al.
NPJ Precision Oncology
|
October 14, 2024
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
Giorgio Corti, Kristi Buzo, Enrico Berrino, et al.
Molecular Oncology
|
May 23, 2025
TRPM8 levels determine tumor vulnerability to channel agonists
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, et al.
Molecular Oncology
|
March 12, 2024
Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer
Elisa Mariella, Gaia Grasso, Martina Miotto, et al.
Plos One
|
May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.
EMBO Molecular Medicine
|
May 19, 2026
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer
Kristi Buzo, Laura Bizzozero, Marilena Lentini, et al.
JAMA
|
October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
Wendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
Nature Communications
|
June 14, 2018
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
Mariangela Russo, Simona Lamba, Annalisa Lorenzato, et al.
Science Translational Medicine
|
February 21, 2014
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
Sandra Misale, Sabrina Arena, Simona Lamba, et al.
The Journal of Clinical Investigation
|
July 29, 2010
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
June 19, 2024
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification
Marco Cortese, Erica Torchiaro, Alice D'Andrea, et al.
NPJ Precision Oncology
|
October 14, 2024
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
Giorgio Corti, Kristi Buzo, Enrico Berrino, et al.
Molecular Oncology
|
May 23, 2025
TRPM8 levels determine tumor vulnerability to channel agonists
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, et al.
Molecular Oncology
|
March 12, 2024
Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer
Elisa Mariella, Gaia Grasso, Martina Miotto, et al.
Plos One
|
May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.
EMBO Molecular Medicine
|
May 19, 2026
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer
Kristi Buzo, Laura Bizzozero, Marilena Lentini, et al.
JAMA
|
October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
Wendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Page
of 6